We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Genome Sequencing More Informative than Cytogenetic Analysis in Myeloid Cancers

By LabMedica International staff writers
Posted on 24 Mar 2021
Print article
Image: The NovaSeq 6000 sequencing instrument (Photo courtesy of Illumina)
Image: The NovaSeq 6000 sequencing instrument (Photo courtesy of Illumina)
Genetic profiling is a routine component of the diagnostic workup for an increasing number of cancers and is used to predict clinical outcomes and responses to targeted therapies. Genomic analysis is essential for risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Whole-genome sequencing is an unbiased method of detecting all types of mutations and could potentially be used to replace current testing algorithms. Such sequencing can also be performed on a limited amount of DNA and can identify genomic changes that may be cryptic in other types of analyses. These features of whole-genome sequencing suggest that it could improve genomic profiling in patients with cancer.

A large team of scientists led by those at Washington University in St. Louis (St. Louis, MO, USA) used a streamlined whole-genome sequencing (ChromoSeq) approach to obtain genomic profiles for 263 patients with myeloid cancers, including 235 patients who had undergone successful cytogenetic analysis. The team analyzed the performance of whole-genome sequencing by comparing their results with findings from cytogenetic analysis and targeted sequencing. Sequencing was performed on NovaSeq 6000 sequencing instruments (Illumina, San Diego, CA, USA). The scientists used fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), chromosomal microarray analyses, and RNA-sequencing data to confirm findings on whole-genome sequencing that had not been detected by cytogenetic analysis.

The investigators reported that whole-genome sequencing detected all 40 recurrent translocations and 91 copy-number alterations that had been identified by cytogenetic analysis. In addition, they identified new clinically reportable genomic events in 40 of 235 patients (17.0%). Prospective sequencing of samples obtained from 117 consecutive patients was performed in a median of five days and provided new genetic information in 29 patients (24.8%), which changed the risk category for 19 patients (16.2%). Standard AML risk groups, as defined by sequencing results instead of cytogenetic analysis, correlated with clinical outcomes. Whole-genome sequencing was also used to stratify patients who had inconclusive results by cytogenetic analysis into risk groups in which clinical outcomes were measurably different.

The authors concluded that whole-genome sequencing provided rapid and accurate genomic profiling in patients with AML or MDS. Such sequencing also provided a greater diagnostic yield than conventional cytogenetic analysis and more efficient risk stratification on the basis of standard risk categories. The authors estimated the cost of WGS, as performed in their study, to be about USD 1,900, putting it in the range of other testing platforms. At high-throughput laboratories the cost could be about USD 1,300. As the cost of sequencing decreases, WGS will likely reach price parity with conventional testing platforms. The study was published on March 11, 2021 in The New England Journal of Medicine.

Related Links:
Illumina
Washington University in St. Louis


Gold Supplier
Pipette Tips
Sapphire Pipette Tips
New
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Undercounter Laboratory Refrigerator
iLR105-GX
New
Flu A/B Antibodies and Antigens
HyTest Flu A/B Antibodies and Antigens

Print article

Channels

Hematology

view channel
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab... Read more

Immunology

view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.